PCT 2012: Wall Street Perspectives: Economic Outlook on Investment Areas Growth Opportunities
Publicly traded CROs have been playing a disappearing act. During the past eight years, 13 contract clinical research service providers that were formerly public companies have moved into the private equity markets. Behind the veil afforded by the private markets, CROs have far greater latitude to not only complete transactions that complement their capacity and expertise and permit a founder to exit, but also to pursue novel leading strategies that may ultimately redefine integrated drug development services in the future. CROs now double the global capacity of drug development professionals and play a critical and essential role in supporting pharmaceutical and biotechnology company R D operations. With a global perspective, this distinguished group of financial leaders offers multi-stakeholder perspectives on the industry #39;s key threats and opportunities. bull; Does a public to private switch gives CROs better chance to "fix" and transform themselves? bull; Assess the difference in strategies between PE owned CROs, Private CROs, and public CROs. What value, do PE firms bring to CROs? bull; Why are private equity firms increasing their investments in CROs? How valuation methodologies to they use to decide what companies to invest in? bull; Is there a conflict of interest in Private equity firms investing in pharma and investing in CROs? Presenters: Moderator: Ian Lauf, MBA, Global Sourcing Manager, Medical Clinical Trial Central Services, Boehringer Ingelheim Pharmaceuticals, Inc ...From:PartnershipsIIRViews:0 0ratingsTime:01:04:24More inScience Technology
View post:
PCT 2012: Wall Street
Recommendation and review posted by G. Smith
